Cantor Fitzgerald Reiterates Neutral on Gilead Sciences, Maintains $70 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald has reiterated its Neutral rating on Gilead Sciences (NASDAQ:GILD) and maintained a $70 price target.
August 09, 2024 | 3:36 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cantor Fitzgerald has reiterated its Neutral rating on Gilead Sciences and maintained a $70 price target.
The reiteration of a Neutral rating and maintenance of the $70 price target suggests that Cantor Fitzgerald does not see significant upside or downside potential in the short term for Gilead Sciences. This is likely to result in a neutral impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100